GeneQuine develops gene therapy-based drugs for the treatment of osteoarthritis. The goal is the development of gene therapy drugs for osteoarthritis in humans. However, veterinary drug development is an attractive area as well because regulatory hurdles, development risk and development costs for veterinary drugs are markedly lower and market approval can be gained faster compared with human medicines. Thus, GeneQuine is also developing drug candidates for horses and dogs.

Management

Kilian Guse

Kilian Guse, PhD

CEO, Co-Founder

Dr. Guse has more than 10 years experience in the field of gene therapy and is author of more than 30 scientific publications in international, peer-reviewed journals and book chapters on this topic.

More

Stanislav Plutizki

Stanislav Plutizki, PhD

Vice President Regulatory and Medical Affairs, Co-Founder

Prior to co-founding and working for GeneQuine, Dr. Plutizki was international medical manager at the regulatory and global medical marketing department at Berlin Chemie AG (Menarini Group), Berlin, Germany, where he was responsible for medical and scientific management of a large product portfolio.

More

Advisory Board

Peter Johann

Peter Johann, PhD

Advisory Board

Dr. Peter Johann is a managing general partner of NGN Capital.

More

Academic Collaborations

Cornell University

Cornell University

Cornell University is an Ivy League research university located in Ithaca, New York, USA.

More

Baylor College of Medicine

Baylor College of Medicine

Baylor College of Medicine (BCM), located in Houston, Texas, USA is one of the leading medical schools and biomedical research institutes in the country.

More